Actionable mutations in muscle-invasive bladder cancer

Current Opinion in Urology

Volumn 23, Issue 5, 2013, Pages 472-478

  Bambury, Richard M ^a   Rosenberg, Jonathan E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Actionable mutations; Bladder cancer; Personalized medicine; Targeted therapy; Urothelial cancer

Indexed keywords

AURORA A KINASE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN D1; DOCETAXEL; DOVITINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; GEMCITABINE; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; PACLITAXEL; PALBOCICLIB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; VINBLASTINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CARCINOMA CELL; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CYSTECTOMY; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENE TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; MUSCLE INVASIVE BLADDER CANCER; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA;

EID: 84881649977     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328363a3cd     Document Type: Review

References (62)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63:11-30
2. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: Narrowing the gap between evidence and practice. J Clin Oncol 2009; 27:5680-5684
3. Dall'Era MA, Cheng L, Pan CX. Contemporary management of muscleinvasive bladder cancer. Expert Rev Anticancer Ther 2012; 12:941-950
4. Neoadjuvant cisplatin methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists Lancet 1999; 354:533-540
5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866
6. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4:CD006243
7. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29:2866-2874
8. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011-2019
9. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-697
10. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25:2218-2224
11. P. Beuzeboc EB, Voog E, Bousquet G,et al. Trastuzumab (T) combined with standard chemotherapy in HER metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study, 2007 ASCO Annual Meeting; J Clin Oncol 2007; 25,18S, abstract 15565
12. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422
13. Press MF, O'Donnell PH, Plimack ER, et al. HER2 expression in patients with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2. 2013 ASCO Genitourinary Cancers Symposium; Orlando, Florida. J Clin Oncol 2013; 31, 6S, abstract 292
14. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancerguideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457:299-307
15. Lae M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann Oncol 2010; 21:815-819
16. Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: A study using formalinfixed, paraffin-embedded archival tissues. Human Pathol 2012; 43:1590-1595
17. Wong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012; 30:3545-3551
18. Grivas P, Agarwal N, Siefker-Radtke AO, et al. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma 2012 ASCO Annual Meeting; Chicago, IL. J Clin Oncol 30, 2012 (suppl; abstr 4506
19. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
20. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): A multicentre, openlabel, randomised phase 3 trial. Lancet Oncol 2012; 13:239-246
21. Blehm KN, Spiess PE, Bondaruk JE, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy. Clin Cancer Res 2006; 12:4671-4677
22. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010; 105:317-321
23. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009; 20:1074-1079
24. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213:91-98
25. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2012; 22:795-803
26. Milowsky MI, Dittrich C, Martinez ID, et al. Final results of a multicenter, openlabel phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3; ASCO 2013 Genitourinary Cancers Symposium, Orlando, FL; J Clin Oncol 31, 2013 (suppl 6; abstr 255
27. Balar AV, Iyer G, Al-Ahmadie H, et al. Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium; San Francisco, CL, J Clin Oncol 30, 2012 (suppl 5; abstr 277
28. Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: The PI3K/Akt/mTOR pathway. Lab Invest 2010; 90:1406-1414
29. Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: Clinical activity, molecular response, and biomarkers. Ann Oncol 2012; 23:2663-2670
30. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338:221
31. Janku F, Wheler JJ, Naing A, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013; 73:276-284
32. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674
33. Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013; In Press
34. Johnson N, Shapiro GI. Cyclin-dependent kinase 4/6 inhibition in cancer therapy. Cell Cycle 2012; 11:3913
35. Finn RS, Crown JP, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER/HER2-Advanced breast cancer (BC); San Antonio Breast Cancer Symposium 2012; San Antonio, Texas, USA; Cancer Res 2012; 72(24 Suppl): Abstract nr S1-6
36. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119:4597-4607
37. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-Amplified well differentiated or dedifferentiated liposarcoma. J Clin Onco 2013
38. Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 2012; 11:2756-2761
39. McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 2012; 11:2747-2755
40. Advanced Bladder Cancer Meta-Analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-Analysis of individual patient data advanced bladder cancer (ABC) meta-Analysis collaboration European Urology 2005; 48:202-206
41. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11:2625-2636
42. Takata R, Katagiri T, Kanehira M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007; 98:113-117
43. Kato Y, Zembutsu H, Takata R, et al. Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genomewide gene expression profiling. Exp Ther Med 2011; 2:47-56
44. Iwasaki K, Obara W, Kato Y, et al. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer. Jpn J Clin Oncol 2013; 43:193-199
45. Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62:523-533
46. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009; 69:8302-8309
47. Chang JS, Lara PN Jr, Pan CX. Progress in personalizing chemotherapy for bladder cancer. Adv Urol 2012; 2012:364919
48. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011; 22:139-144
49. Richardson PG, Mitsiades CS, Laubach JP, et al. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Brit J Haematol 2011; 152:367-379
50. Garg M,Kanojia D,Seth A, et al.Heat-shock protein 70-2(HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur J Cancer 2010; 46:207-215
51. Tatokoro M, Koga F, Yoshida S, et al. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer 2012; 131:987-996
52. Kamada M, So A, Muramaki M, et al. Hsp27 knockdown using nucleotidebased therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007; 6:299-308
53. Hadaschik BA, Jackson J, Fazli L, et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of nonmuscle-invasive bladder cancer. BJU Int 2008; 102:610-616
54. Kim SJ, Jang JE, Cheong JW, et al. Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells. Korean J Hematol 2012; 47:178-185
55. Comperat E, Bieche I, Dargere D, et al. Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. Urology 2008; 72:873-877
56. Lei Y, Yan S, Ming-De L, et al. Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochemica 2011; 113:514-518
57. Matulonis UA, Sharma S, Ghamande S, et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynec Oncol 2012; 127: 63-69
58. Yamamoto Y, Matsuyama H, Kawauchi S, et al. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006; 70:231-237
59. Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol 2011
60. Stadler WM, Vaughn DJ, Sonpavde G, et al. Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC) ASCO Annual Meeting; 2011. J Clin Oncol 29: 2011 (suppl; abstr 4567
61. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-1703
62. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-529